Sorafenib and Bevacizumab in Treating Patients With Advanced Kidney Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborator:
Information provided by:
Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT00126503
First received: August 2, 2005
Last updated: February 28, 2011
Last verified: February 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
Publications:
Puzanov I, Flaherty KT, Atkins MB: Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-19, 2007.
Sosman JA, Flaherty K, Atkins MB, et al.: A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). [Abstract] J Clin Oncol 24 (Suppl 18): A-3031, 128s, 2006.